Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer Academic Article uri icon

Overview

MeSH Major

  • Cerebellar Neoplasms
  • Cranial Fossa, Posterior
  • Medulloblastoma

abstract

  • BKM120 and olaparib can be co-administered, but the combination requires attenuation of the BKM120 dose. Clinical benefit was observed in both gBRCAm and gBRCAwt pts. Randomized phase II studies will be needed to further define the efficacy of PI3K/PARP-inhibitor combinations as compared with a PARP inhibitor alone.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1093/annonc/mdw672

PubMed ID

  • 27993796

Additional Document Info

start page

  • 512

end page

  • 518

volume

  • 28

number

  • 3